Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid

Exclusion Criteria

• •1. Patients who, during the parent dupilumab study, R668-BP-1902 (NCT04206553), developed a serious adverse event (SAE) and/or adverse event (AE) deemed related to program drug and which led to discontinuation of investigational product
• •2. Treatment with non-steroidal immunosuppressive/immunomodulating drug(s) (eg, mycophenolate mofetil, azathioprine, or methotrexate) within 4 weeks before the baseline visit
• •3. Treatment with BP-directed biologics, as defined in the protocol
• •4. Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit
• •5. Planned or anticipated use of any prohibited medications or procedures during program treatment
• •6. Severe concomitant illness(es) that, in the treating physician's judgment, would adversely affect the patient's participation in the program